BTIG raised the firm’s price target on Verastem (VSTM) to $20 from $13 and keeps a Buy rating on the shares after the company announced the FDA accepted its new drug application filing for avutometinib in combination with defactinib for the treatment of adult patients with recurrent low-grade serous ovarian cancer who received at least one prior systemic therapy and have a KRAS mutation under priority review with an FDA action date set for June 30, 2025. The firm e expects FDA approval for the combination by mid-2025, marking the first FDA approved treatment option for women with KRAS mutant low-grade serous ovarian cancer. With FDA acceptance of the application under priority review, and its increased confidence following a recent key opinion leader call, BTIG increased its modeled probability of success from 65% to 80% for avutometinib.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- 3 Best Stocks to Buy Now, 12/31/2024, According to Top Analysts
- Verastem announces FDA acceptance and Priority Review of NDA for Avutometinib
- Verastem jumps 50% to $5.50 on FDA priority review for Avutometinib
- Verastem price target raised to $9 from $7 at Mizuho
- Verastem announces preliminary avutometinib and sotorasib data
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue